SciMed Solutions

"One of the very common approaches in drug discovery is something called docking..." - Chuck Reynolds, Founder of Gfree Bio

In the latest episode of the SciMed Biotech Podcast, Dr. Charles Reynolds explains how docking simulations allow scientists to test how potential drug molecules might bind to their targets before they’re ever synthesized in the lab.

By modeling these interactions computationally, researchers can better understand molecular behavior and design more effective drug candidates.

Listen to the full episode here: https://www.scimed.io/news/chuck-reynolds-gfree-bio

hashtag hashtag hashtag

In a prior episode of the SciMed Biotech Podcast, we spoke with Matthew Gdovin, Founder and Chief Science Officer of Vitanova Biomedical, about a cancer treatment approach built around light-activated intracellular acidosis (LAIA).

Matthew breaks down how Vitanova’s platform uses upconverting nanoparticles and deep-penetrating light to trigger intracellular processes that selectively induce cancer cell death. We discuss why intracellular pH regulation is a compelling therapeutic target, how light activation enables precise control, and what it takes to move a physics-driven therapy from the lab toward clinical application.

If you’re interested in how emerging cancer therapies are being engineered at the cellular level, this episode is worth revisiting.

Listen now on our website.

🎧 https://scimed.io/news/matthew-gdovin-vitanova-biomedical

SciMed Biotech Podcast with Matthew Gdovin of Vitanova Biomedical — SciMed This episode features an exciting conversation with Matthew Gdovin, the Founder and Chief Science Officer of Vitanova Biomedical. Delve into the technology behind Vitanova’s cancer treatments as Matthew explains their proprietary light-activated intracellular acidosis (LAIA) therapy, which targets...